North Brunswick, NJ – According to filings with the U.S. Securities and Exchange Commission, Genomic Prediction is raising $12,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Laurent Melchior played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Genomic Prediction
Genomic Prediction provides advanced genomic tests which improve IVF health outcomes. Genomic Prediction Inc. (GP) was incorporated in Delaware, May 1, 2017. The research insights which led to the creation of GP stretch back much further. Research and data exchange agreements to develop molecular methodology, signed with some of the largest biotechnology vendors in the world, were ongoing as early as 2015. In the decade prior, the founders work in embryology, detection of chromosomal abnormality, computational genomics, algorithms, and polygenic architecture led to GPs superior and innovative methodology for the genetic testing of human embryos. GPs products incorporate fundamental improvements on existing methods.

To learn more about Genomic Prediction, visit http://www.lifeview.com/

Contact:
Laurent Melchior, Chief Executive Officer
646-954-7144

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved